News stories about Achillion Pharmaceuticals (NASDAQ:ACHN) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.8528125071643 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) – Important Factors to Analyse A Good Investment – Nasdaq Journal (press release) (nasdaqjournal.com)
- Achillion Pharmaceuticals, Inc. (ACHN): Institutional Holdings and Trading Data – Market Movers (financialqz.com)
- Attention Seeking Stock – Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) – Alpha Beta Stock (alphabetastock.com)
- Technical data from the actions of people on Achillion Pharmaceuticals, Inc. (ACHN) – Wall Street Morning (wallstreetmorning.com)
- Stocks Messing With The Heads Of Investors: Ironwood Pharmaceuticals, Inc. (IRWD), Achillion Pharmaceuticals, Inc … – Market Movers (financialqz.com)
ACHN has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research report on Monday, November 6th. Leerink Swann reiterated a “buy” rating and issued a $5.00 target price on shares of Achillion Pharmaceuticals in a research report on Monday, December 11th. Chardan Capital reiterated a “neutral” rating on shares of Achillion Pharmaceuticals in a research report on Sunday, September 17th. Finally, BidaskClub upgraded shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 21st. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. Achillion Pharmaceuticals has an average rating of “Hold” and an average target price of $5.13.
Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.04. During the same quarter last year, the firm earned ($0.15) earnings per share. sell-side analysts anticipate that Achillion Pharmaceuticals will post -0.63 earnings per share for the current year.
In other news, major shareholder & Johnson Johnson sold 18,367,346 shares of the stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $2.75, for a total value of $50,510,201.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.24% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Achillion Pharmaceuticals (ACHN) Given Coverage Optimism Score of 0.10” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.com-unik.info/2018/01/12/achillion-pharmaceuticals-achn-given-coverage-optimism-score-of-0-10.html.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
What are top analysts saying about Achillion Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Achillion Pharmaceuticals and related companies.